Hunter Smith - Nov 24, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Financial Officer
Signature
/s/ Hunter Smith
Stock symbol
RYTM
Transactions as of
Nov 24, 2023
Transactions value $
-$308,835
Form type
4
Date filed
11/28/2023, 04:05 PM
Previous filing
Nov 16, 2023
Next filing
Dec 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $75.5K +11K +17.87% $6.88 72.4K Nov 24, 2023 Direct
transaction RYTM Common Stock Sale -$384K -11K -15.16% $35.02 61.4K Nov 24, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -11K -7.36% $0.00 138K Nov 24, 2023 Common Stock 11K $6.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $35.00 to $35.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock options is fully vested.